STL Index for: Catherine McCuaig
Optimal Use of Crisaborole in Atopic Dermatitis – An Expert Guidance Document
Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings
The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.
